Aduro BioTech Inc (NASDAQ:ADRO) has analysts on the Bullish side this week.

July 17, 2017 - By Marguerite Chambers

 Aduro BioTech Inc (NASDAQ:ADRO) has analysts on the Bullish side this week.

Aduro BioTech Inc (NASDAQ:ADRO) Ratings Coverage

Among 6 analysts covering Aduro Biotech (NASDAQ:ADRO), 3 have Buy rating, 1 Sell and 2 Hold. Therefore 50% are positive. Aduro Biotech had 10 analyst reports since August 19, 2015 according to SRatingsIntel. Bank of America downgraded Aduro BioTech Inc (NASDAQ:ADRO) rating on Tuesday, March 15. Bank of America has “Underperform” rating and $14 target. The firm has “” rating by Leerink Swann given on Wednesday, August 19. The stock of Aduro BioTech Inc (NASDAQ:ADRO) earned “Perform” rating by Oppenheimer on Tuesday, December 1. The rating was initiated by Oppenheimer with “Outperform” on Tuesday, October 20. The firm earned “Buy” rating on Tuesday, November 24 by TH Capital. The rating was maintained by Roth Capital with “Buy” on Tuesday, November 24. The stock has “Buy” rating by Roth Capital on Thursday, August 27. The rating was maintained by Roth Capital on Tuesday, March 7 with “Buy”. FBR Capital maintained Aduro BioTech Inc (NASDAQ:ADRO) rating on Tuesday, May 17. FBR Capital has “Outperform” rating and $22 target. The company was upgraded on Thursday, September 3 by Zacks. Below is a list of Aduro BioTech Inc (NASDAQ:ADRO) latest ratings and price target changes.

07/03/2017 Broker: Roth Capital Rating: Buy New Target: $17.00 Maintain

It closed at $12.7 lastly. It is down 1.22% since July 17, 2016 and is uptrending. It has underperformed by 15.48% the S&P500.

Aduro Biotech, Inc. is an immunotherapy company, which focuses on the discovery, development and commercialization of therapies that manage the treatment of various diseases, including cancer. The company has market cap of $894.95 million. The Company’s product candidates from its Live, Attenuated, Double-Deleted Listeria monocytogenes, Stimulator of Interferon Genes Pathway Activator, and B-select monoclonal antibody platforms are designed to stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies, as well as other immunotherapies. It currently has negative earnings. The Company’s LADD technology platform is being developed as a treatment for multiple indications, including mesothelioma, ovarian, gastric, lung and prostate cancers.

More notable recent Aduro BioTech Inc (NASDAQ:ADRO) news were published by: which released: “Aduro Biotech, Inc. (Nasdaq: ADRO) to Ring The Nasdaq Stock Market Opening Bell” on March 27, 2017, also with their article: “Aduro Biotech Announces Upcoming Data Presentations at the 2017 American …” published on March 06, 2017, published: “Partial Clinical Hold Lifted and Enrollment Resumes for Aduro Biotech LADD …” on November 21, 2016. More interesting news about Aduro BioTech Inc (NASDAQ:ADRO) were released by: and their article: “Aduro Biotech Enters into Exclusive License Agreement for Proprietary …” published on January 19, 2017 as well as‘s news article titled: “Aduro Biotech (ADRO) Earns $2M Milestone Payment Relating to Collaboration …” with publication date: July 13, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.